Please use this identifier to cite or link to this item:
|Title:||Transcription-mediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C|
|Authors:||Bastos, Dauana O. [UNIFESP]|
Perez, Renata M.
Souza e Silva, Ivonete Sandra de [UNIFESP]
Lemos, Lara Barros [UNIFESP]
Simonetti, Jose Pascoal
Medina-Pestana, Jose Osmar [UNIFESP]
Silva, Antonio Eduardo B. [UNIFESP]
Ferraz, Maria Lucia [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Rio de Janeiro (UFRJ)
|Citation:||Journal of Medical Virology. Malden: Wiley-Blackwell, v. 84, n. 4, p. 596-600, 2012.|
|Abstract:||The diagnosis of hepatitis C virus (HCV) infection in hemodialysis patients is difficult particularly due to the presence of intermittent viremia. the aims of this study were: (a) to determine the prevalence of intermittent viremia in hemodialysis patients with anti-HCV antibodies who tested negative for HCV RNA by PCR at the first evaluation and (b) to evaluate the contribution of the transcription-mediated amplification method (TMA) to the diagnosis of viremia in the PCR-negative samples. One hundred and six patients with anti-HCV antibodies and an initial negative result for HCV RNA by PCR were included. An additional sample was collected for a second HCV RNA test by PCR after a minimum interval of 3 months and a positive result characterized intermittent viremia. HCV RNA was investigated by TMA in the PCR-negative sample of patients with intermittent viremia, and in the most recent sample from patients with PCR-negative results in both determinations. Intermittent viremia was observed in 60/106 (57%) patients (57% men; age: 45 +/- 10 years). Fifty-one of the 60 negative samples from patients with intermittent viremia and 29/46 double-negative patients were tested by TMA. This assay detected viremia in 20/51 (39%) samples of intermittent viremia and in 2/29 (7%) of double-negative samples. the results showed that intermittent viremia is frequent in hemodialysis patients who tested negative for HCV RNA by PCR. Therefore, a second HCV RNA test is necessary for all HCV RNA-negative patients. the TMA assay appears to be the best first screening test for viremia in this population. J. Med. Virol. 84:596600, 2012. (C) 2011 Wiley Periodicals, Inc.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.